“Screening recommendations for this age group continue to be debated,” said Bonnie N. Joe, M.D., Ph.D., associate professor in residence and chief of women’s imaging at University of California, San Francisco (UCSF)…
“Because this work shows we can dramatically reduce metastasis in pre-clinical models, and because the drug is already FDA approved for HIV treatment- we may be able to test soon whether this drug can block metastasis in patients with prostate cancer,” says Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University and senior author on the study. The work builds on previous research from Dr. Pestell’s lab that showed in 2012 that CCR5 signaling was key in the spread of aggressive forms of breast cancer to the lungs…
A team led by University of Alberta biochemistry professor David Brindley found that inhibiting the activity of an enzyme called autotaxin decreases early tumour growth in the breast by up to 70 per cent. …
“You don’t eat wild cucumber, unless you want to use it as a purgative,” said William Lucas, professor of plant biology at the University of California, Davis and coauthor on the paper to be published Nov. 28 in the journal Science. That bitter flavor in wild cucurbits — the family that includes cucumber, pumpkin, melon, watermelon and squash — is due to compounds called cucurbitacins. The bitter taste protects wild plants against predators. …
“Because this work shows we can dramatically reduce metastasis in pre-clinical models, and because the drug is already FDA approved for HIV treatment- we may be able to test soon whether this drug can block metastasis in patients with prostate cancer,” says Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University and senior author on the study. The work builds on previous research from Dr. …
Now research in an animal model finds that a novel combination therapy, which couples low-dose chemotherapy with an antiangiogenic treatment, resulted in better survival rates compared with standard therapy. Led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and the University of Guelph, the findings show that the agent, 3TSR, not only led to tumor regression, but also improved tumor blood flow and enabled more efficient delivery of much smaller and less toxic doses of chemotherapy. The study currently appears online in The Journal of the Federation of American Societies for Experimental Biology (FASEB) and will be published in the February 2015 print issue. …
Of course, researchers have extensively targeted these two signaling pathways, designing drugs that turn on or off genes in these pathways, thus interrupting the transmission of cancer-causing signals. Unfortunately, these pathways have proven difficult to drug and also it has been difficult to show the effectiveness of drugs that successfully interrupt the transmission of signals along these pathways. A study by the University of Colorado Cancer Center published in the journal PLoS ONE and concurrent phase I clinical trial is examining a new strategy: targeting both these important cancer-causing pathways simultaneously. “Well, these two pathways are mutated frequently in cancer. …
Researchers from Royal Holloway, University of London, together with an international team from across the United States and Europe, have found that people with a specific variant of a gene, known as PHACTR1, are at reduced risk of suffering cervical artery dissection, which is caused by a tear in an artery that leads to the brain. The new discovery, published in the journal Nature Genetics, could lead to new treatments and prevention strategies for the disease, which is a major cause of stroke in young adults. The same gene variant has also been identified as a protector against migraines and affects the risk of heart attack. Professor Pankaj Sharma, from the School of Biological Sciences at Royal Holloway, said: “This is an important breakthrough…
Researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J…
Patients who were told they had a 1-in-10 chance of winning $50 were more likely to complete home stool blood tests that help screen for colon cancer, according to a new study led by a researcher at the VA Ann Arbor Healthcare System and University of Michigan. The findings appear in a special issue of Annals of Internal Medicine…